The analysts cut its rating on Alcon shares to “neutral” from “overweight” and lowered its price target to SFr 62.8 for June 2027, down from SFr 94.7 for June 2026. The reduced target reflects lower ...

Alcon AG (NYSE:ALC) saw its stock fall more than 2% on Thursday following a rating cut by J.P. Morgan, citing disappointing quarterly performance and reduced visibility on earnings. David Adlington, ...

Alcon (NYSE:ALC) stock continues to decline as J.P. Morgan downgrades the company following mixed Q2 2025 results and lowered sales guidance. Read more here.

JPMorgan analyst David Adlington downgraded Alcon (ALC) to Neutral from Overweight with a price target of $77.53, down from $105.88. The company ...

Alcon affirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus consensus of $3.12. The company lowered 2025 sales guidance from $10.4 billion-$10.5 billion to $10.3 billion-$10.4 billion, ...

JP Morgan’s European desk has upgraded Alcon (ALC) to overweight, commenting that concerns about growth in the implantables market is likely to be “short-lived.” Read more here.

Biotech Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO By James Waldron Mar 27, 2025 9:23am Aurion Biotech Alcon investor lawsuit mergers and acquisitions ...